Industry
From U.S. (Toll Free) : +16467917070    |   UK : +442030260021     |    sales@businessmarketinsights.com

North America Dermatology OTC Medications Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type (Tablets and Capsules, Gels, Creams and Ointments, and Others), Route of Administration (Topical and Oral), Indication (Dermatitis, Acne, Psoriasis, Skin Bleaching, Fungal Disease, Warts, and Others), and Distribution Channel (Online Distribution and Offline Distribution)   

Report Code :  BMIRE00025067
No. of Pages :  185
Published Month :  Jun 2022
Category :  Life Sciences
$299 per month

Best Plan
  • All Reports in One Industry
  • All Reports Read Access
  • Subscription Duration : 12 Months
  • Monthly New Reports Added
  • $1200 Yearly Saving

The North America dermatology OTC medications market is expected to grow from US$ 6,289.64 million in 2021 to US$ 8,721.90 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2021 to 2028.

Skin issues such as pigmentation, wrinkles, creases, acne, and burn scars are common among the masses. The costs associated with acne treatment and lost productivity among those receiving acne treatment exceeded US$ 1.2 billion in 2013; more than 5.1 million people, primarily children, and young adults, were seeking medical treatment for acne in the same year. Further, 1 in 10 people develops atopic dermatitis during their lifetime, and the condition affects up to 25% of children and 2–3% of adults. According to the American Academy of Dermatology Association, acne is the most common skin condition in the US, affecting ~50 million Americans annually. Additionally, ~85% of people aged 12–24 experience minor acne problems. In 2021, according to a poll conducted by Dermstore with 2,000 women across the US, young women started using products to reduce the signs of aging much sooner than older women. Acne vulgaris is becoming more prevalent in every country. Dermatology OTC medications are widely used in the treatment of acne. According to the Global Burden of Disease Study 2019, 117.4 million incident cases of acne vulgaris, 231.2 million prevalent cases, and 5 million disability-adjusted life years (DALYs), representing a 48% increase since 1990. Thus, the high prevalence of skin disease supports the dermatology OTC medications market's growth.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America dermatology OTC medications market. The North America dermatology OTC medications market is expected to grow at a good CAGR during the forecast period. 

 

North America Dermatology OTC Medications Market Revenue and Forecast to 2028 (US$ Million)


North America Dermatology OTC Medications Market Segmentation  

 

The North America dermatology OTC medications market is segmented into product type, route of administration, indication, distribution channel, and country. Based on product type, the market is segmented into tablets and capsules, gels, creams and ointments, and others. The creams and ointments segment dominated the market in 2020; however, the tablets and capsules segment is expected to be the fastest growing during the forecast period. Based on route of administration, the market is segmented into topical and oral. The topical segment dominated the market in 2020; however, the oral segment is expected to be a faster growing segment during the forecast period. Based on indication, the market is segmented into dermatitis, acne, psoriasis, skin bleaching, fungal disease, warts, and others. The acne segment dominated the market in 2020 and is expected to be the fastest growing segment during the forecast period. The dermatitis segment is further classified into atopic dermatitis, contact dermatitis, and others. The acne segment is further segmented into non-inflammatory acne and inflammatory acne. The psoriasis segment is further segmented into plaque psoriasis, guttate psoriasis, and others. The fungal disease is further segmented into athlete's foot, ringworm, fungal nail infections, and others. Moreover, the warts segment is further segmented into common warts, flat warts, and others. Based on distribution channel, the market is segmented into online distribution and offline distribution. The offline distribution segment dominated the market in 2020; however, the online distribution segment is expected to be a faster segment during the forecast period. The offline distribution is further segmented into retail and hospital pharmacies and super and hypermarkets. Based on country, the market is segmented into the US, Canada, and Mexico.      

 

Acella Pharmaceuticals, LLC; Bausch Health Companies Inc.; Bayer AG; Dr. Reddy's Laboratories; Galderma; GlaxoSmithKline plc.; Johnson and Johnson Services, Inc.; LEO Pharma A/S; Perrigo Company plc; and Viatris Inc. are among the leading companies in the North America dermatology OTC medications market. 

  1. Acella Pharmaceuticals, LLC
  2. Bausch Health Companies Inc.
  3. Bayer AG
  4. Dr. Reddy's Laboratories
  5. Galderma
  6. GlaxoSmithKline plc.
  7. Johnson and Johnson Services, Inc.
  8. LEO Pharma A/S
  9. Perrigo Company plc
  10. Viatris Inc.  
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America dermatology OTC medications market.      
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the North America dermatology OTC medications market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the dermatology OTC medications market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution